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impact of season on the association 
between vitamin D levels at 
diagnosis and one-year remission in 
early Rheumatoid Arthritis
M. Herly  1,2,3 ✉, K. Stengaard-pedersen  4, P. Vestergaard  5, R. christensen  1,6,  
S. Möller  3, M. Østergaard  7, P. Junker  1, M. L. Hetland  7, K. Hørslev-petersen  8 & 
t. ellingsen  1
the study evaluates associations between serum vitamin D metabolites at diagnosis and one-year 
remission, in early diagnosed rheumatoid arthritis(RA). The CIMESTRA-cohort comprised 160 newly 
diagnosed RA patients, treated aiming at remission. Vitamin D supplementation was recommended 
according to national guidelines. Dtotal(25OHD2 + 25OHD3) was dichotomized at 50 nmol/L, 1,25(OH)2D 
was categorized in tertiles. Primary outcome was remission(DAS28-CRP ≤ 2.6) after one year. 
Associations were evaluated using logistic regression, further adjusted for pre-specified potential 
confounders: Age, sex, symptom-duration before diagnosis, DAS28-CRP and season of diagnosis. 
Results are presented as Odds Ratios(OR) with 95% Confidence Intervals(95%CIs). In univariate 
analyses, neither Dtotal nor 1,25(OH)2D were associated with remission. In adjusted analyses, low Dtotal 
was associated with higher odds for remission; OR 2.6, 95%CI (1.1; 5.9) p = 0.03, with season impacting 
results the most. one-year remission was lower in patients with diagnosis established at winter. in 
conclusion, low Dtotal at diagnosis was associated with increased probability of achieving one-year 
remission in early RA when adjusting for covariates. Diagnosis in winter was associated with lower odds 
for one-year remission. Results suggest that season act as a contextual factor potentially confounding 
associations between vitamin D and RA disease-course. The finding of low Dtotal being associated with 
higher one-year remission remains speculative.
Mounting evidence suggests vitamin D as an important immune-modulator1,2. Circulating 25OHD3 is pro-
duced in the skin upon sun-exposure, dependent on e.g. season and latitude3, and circannual variation 
in 25OHD is well-known in Northern latitude4. 25OHD serves as substrate for conversion into the active 
metabolite; 1,25(OH)2D, both in the kidneys3 and locally in macrophages, dendritic cells and lymphocytes5. 
Immunomodulation by sufficient levels of 1,25(OH)2D includes altered differentiation and maturation of den-
dritic cells, macrophages and lymphocytes5, and inhibition of pro-inflammatory cytokines6. The main-effect 
of vitamin D on the immune system is to balance the immune-response away from the self-aggressive Th1/
Th17-response and towards the tolerogenic Th2/Th-regulatory response7,8.
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In Rheumatoid Arthritis (RA), a chronic inflammatory symmetric arthritis9, low levels of 25OHD are reported 
to be associated with markers of disease activity in cross-sectional settings10,11. 1,25(OH)2D is rarely evaluated, 
but seems to be inversely associated with several markers of disease activity in cross-sectional settings12.
An aggressive aiming-at-remission treatment strategy is the golden standard in RA13, and the 
immune-modulating activity of vitamin D and association with disease activity in cross-sectional studies sug-
gests potential association between vitamin D and remission in RA. To the best of knowledge, only two rather 
small longitudinal studies evaluate associations between serum 25OHD at time of RA diagnosis and remission 
during follow-up14,15. Both studies report lower odds of remission in RA-patients with low 25OHD at diagnosis. 
Association between 1,25(OH)2D and remission was not evaluated.
The objectives of the current study were, in 158 early diagnosed, treatment-naïve Danish RA patients, to meas-
ure serum Dtotal and 1,25(OH)2D at time of diagnosis, and to analyze for associations with remission evaluated as 
Disease Activity Score based on 28 joints and C-reactive Protein (DAS28-CRP) ≤ 2.6 after one year. This was done 
to test the pre-specified hypothesis that baseline vitamin D metabolites are associated with achieving remission 
in early RA.
Results
At diagnosis, median Dtotal was 53.7 nmol/l, IQR 36-67. Median 1,25(OH)2D was 95.5 pmol/l, IQR 70–119. 
Sixty-seven patients (42%) had Dtotal below 50 nmol/L.
Obesity (BMI > 30 kg/m2) was significantly more prevalent in the low Dtotal group (30% versus 13%, p = 0.01) 
as a result of weight being higher (median 79 kg versus 73 kg, p = 0.03) and 1,25(OH)2D was significantly lower 
(median 82 pmol/L versus 110 pmol/L, p < 0.001) No other baseline variables were significantly different between 
Dtotal groups. (See Table 1) One-hundred-and-forty-three of the 158 patients included at baseline had disease 
activity evaluated one year after diagnosis, and were eligible for evaluation of remission. (See Fig. 1).
Results of univariate logistic regression. Diagnosis established at winter compared to summer (OR 
0.4, 95% CI (0.2; 0.9) p = 0.02), Number of Tender Joints (NTJ) (OR 0.9; 95% CI (0.88; 0.98) p = 0.01) and 
DAS28-CRP (OR 0.7, 95% CI (0.5; 0.9) p = 0.01) at time of diagnosis were significantly inversely associated with 
one-year remission, independently of vitamin D metabolite levels. This indicates that it is less likely that patients 
diagnosed during the winter season and in patients with high NTJ or DAS28-CRP at time of diagnosis, will 
achieve remission. [See appendix Table 1].
Primary analysis, evaluating Dtotal groups. At year one, 96 (61%) of the 143 patients were in remission, 
45 (71%) from the group with low Dtotal at diagnosis, and 51 (64%) from the group with normal Dtotal at diagnosis. 
(See Table 2).
No significant association was found between baseline Dtotal group and remission rates in the crude model; OR 
1.4, 95% CI (0.7; 2.7) p = 0.33, whereas the fully adjusted model showed statistical significantly increased odds for 
one year remission; OR 2.6, 95% CI (1.1; 5.9) p = 0.03, in patients with low Dtotal at time of diagnosis compared 
to patients with normal Dtotal. (See Table 2) For details on the definition of crude and adjusted models, see the 
method section. Propensity score analysis including several other factors, potentially affecting the results, did not 
significantly alters the estimate; OR 2.5, 95% CI (1.1; 5.8) p = 0.03, indicating that the further included factors 
have only negligible influence. In the fully adjusted model, remission was further inversely associated with diag-
nosis established in winter; OR 0.3 95% CI (0.1; 0.7) p < 0.01) and DAS28-CRP at diagnosis; OR 0.6 95% CI (0.4; 
0.9) p = 0.01 and directly associated with age at diagnosis; OR 1.04, 95% CI (1.0; 1.1) p = 0.03. Stepwise inclusion 
of the pre-specified variables sex, age, symptom duration, DAS28-CRP at diagnosis and season at diagnosis indi-
cates that especially adjustment for season impacts the estimates in the fully adjusted model. (See Table 3). There 
was no significant interaction between Dtotal levels and season of diagnosis (p = 0.7).
Model fit was tested to evaluate which model best describes the association between vitamin D metabolites, 
one year remission and the chosen, potential confounding variables: A likelihood-ratio test showed that fully 
adjusting the model improved the model fit significantly, whereas the partially adjusted model (including only 
sex and age at inclusion) did not improved the model fit compared to the crude model. In addition, Akaike 
Information criterion (AIC) decreased and Bayesian Information Criterion (BIC) increased when including all 
confounding variables. As we put emphasis on AIC, this is interpreted as the fully adjusted model being the 
model which most adequately describes the real world, resulting in the best balance between number of included 
variables and precision.
To estimate whether missing data for one-year remission affects the results, best- and worse case-scenarios 
were evaluated. These suggested potentially consequences of missing data, as estimates became insignificant in 
best-case scenarios. (See Table 2).
Secondary analysis, evaluating 1,25(OH)2D tertiles. Associations between the active vitamin D 
metabolite and one-year remission were evaluated similar to the primary analyses for Dtotal. No difference existed 
in odds of remission between patients with the lowest 1,25(OH)2D tertile compared to highest, neither in the 
univariate model; OR 1.3, 95% CI (0.5; 3.2) p = 0.59, nor in the fully adjusted model; OR 1.8, 95% CI (0.6; 4.9) 
p = 0.28.
Remission was negatively associated with diagnosis established at winter; OR 0.4 95% CI (0.2; 0.9) 
p = 0.03, and DAS28-CRP at diagnosis; OR 0.6 95% CI (0.4; 0.9) p = 0.01. [See appendix Table 2].Applying 
likelihood-ratio-test, both the partially and fully adjusted model showed significantly better fit than the crude 
model. AIC decreased with each successive adjustment, while BIC decreased from crude to fully adjusted model.
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Discussion
Main finding is that the inverse association between serum Dtotal status at diagnosis and one year remission exists 
only in the model adjusted for season. Although largely unexplained, being diagnosed with RA in the winter is 
independently associated with lower odds for remission after one year of intensive treatment, suggesting that 
season confounds the association between vitamin D and RA disease activity.
The immunomodulatory properties of vitamin D are exerted through local conversion of 25OHD into 
1,25(OH)2D1,5. Subjects with low serum Dtotal lack substrate for the local production of 1,25(OH)2D16,17, increas-
ing the risk of an auto-aggressive Th1/Th17 response18. We surmise that our results support the potential 
existence of a “low vitamin D RA-subtype”, which upon anti-inflammatory treatment and relevant vitamin D 
supplementation is easily treated to remission. On the contrary, subjects with normal Dtotal levels and thus suffi-
cient substrate for local 1,25(OH)2D production, who develop RA may be representative of an immune system 
being more imbalanced and distressed, and thus less susceptible to achieve remission, despite relevant treatment. 
Alternatively, our results indicate the presence of a “Winter-diagnosed RA-subtype”. Patients diagnosed at winter 
will inevitably have one-year remission evaluated the following winter, where the seasonal impact on disease 
activity will decrease probability of remission. Though, our study-design does not allow us to speculate whether 
“winter-diagnosed RA” is less prone to achieve remission in the summer, as we have no half-yearly evaluations.
Our results conflict with other studies evaluating vitamin D and remission in early RA: As opposed to the 
current study, the comparable studies did not adjusted for season in the statistical analyses, but handled potential 
annual impact through study design: One study is located in Columbia, a tropical country with no seasons15, 
while the Italian study14 only evaluated serum 25OHD in the autumn-winter-period, to minimize the seasonal 
Low Dtotal (<50 
nmol/L) N = 67 (42%)
Normal Dtotal (≥50 
nmol/L) N = 91 (58%)
Group comparison 
(p-value) Total N = 158
Age at inclusion, Years Median 52IQR 44–63
Median 53
IQR 41–63 0.83
Median 53
IQR 43–63
Female sex N = 42 (63%) N = 62 (68%) 0.48 N = 104 (66%)
Symptom duration prior to 
diagnosis, months
Median 3.3
IQR 2.4–4.8
Median 3.2
IQR 2.5–4.4 0.81
Median 3.2
IQR 2.5–4.6
Ciclosporin (yes) N = 36 (54%) N = 42 (46%) 0.35 N = 78 (49%)
ACPA-status positive N = 39 (58%) N = 53 (58%) 0.99 N = 92 (58%)
IgM-RF-status positive N = 39 (58%) N = 63 (69%) 0.15 N = 102 (65%)
NTJ (0 to 28) Median 10IQR 6–16
Median 10
IQR 5–15 0.25
Median 10
IQR 5–15
NSJ (0 to 28) Median 9IQR 5–12
Median 8
IQR 5–12 0.67
Median 8
IQR 5–12
VASpatient-global (0 to 100 mm)
Median 50
IQR 26–72
Median 50
IQR 29–72 0.61
Median 50
IQR 29–72
VASpatient-pain (0 to 100 mm)
Median 48
IQR 27–72
Median 46
IQR 29–72 0.96
Median 48
IQR 29–70
VASdoctor-global(0 to 100 mm)
Median 58
IQR 42–70
Median 55
IQR 36–68 0.41
Median 58
IQR 38–68
ESR, mm/hour Median 32IQR 9–48
Median 23
IQR 11–47 0.65
Median 28
IQR 10–47
CRP, nmol/L Median 24IQR 9–51
Median 17.3
IQR 9–39 0.19
Median 20.2
IQR 9–43
DAS28-CRP (0 to 9) Median 5.3IQR 5.6–6.1
Median 5.2
IQR 4.4–5.9 0.32
Median 5.3
IQR 4.5–5.9
HAQ (0 to 3) Median 1IQR 0.5–1.5
Median 0.9
IQR 0.4–1.5 0.88
Median 0.7
IQR 0.4–1.5
Creatinine µmol/L Median 75IQR 67–82
Median 77
IQR 68–83 0.53
Median 76
IQR 67–82
BMI ≥ 30 (kg/m2) N = 20 (30%) N = 12 (13%) 0.01 N = 32 (20%)
Weight, kg Median 79IQR 64–92
Median 73
IQR 64–82 0.03
Median 76
IQR 64–85
Height, cm Median 170IQR 166–175
Median 170
IQR 164–175 0.76
Median 170
IQR 165–175
1,25(OH)2D, pmol/L
Median 82
IQR 65–99
Median 110
IQR 80–139 <0.001
Median 95.5
IQR 70–119
Season of diagnosis (Winter) N = 44 (66%) N = 37 (41%) 0.002 N = 81 (51%)
Table 1. Baseline characteristic according to Dtotal status at diagnosis. Abbreviations: Dtotal: The sum of 25OHD2 
and 25OHD3. ACPA: Anti Citrullinated Protein Antibodies, IgM-RF: Immunoglobulin M Rheumafactor, 
NTJ: Number of Tender Joints, NSJ: Number of Swollen Joints, VAS: Visual Analogue Score, ESR: Erythrocyte 
Sedimentation rate, CRP: C-reactive protein, DAS28-CRP Disease Activity Score, based on 28 joint count and 
CRP. HAQ: Health Assessment Questionnaire, BMI: Body Mass Index. Data as observed. Significant results in 
bold.
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impact. However, RA is diagnosed all year round, and circannual changes in light and darkness is unavoidable in 
Scandinavia. We find the current study to be representative of a Scandinavian, early diagnosed RA-cohort, and 
further sheds light on an important contextual factor in evaluation of disease activity in early RA.
The impact of season on vitamin D levels is well-known3,4 Similarly, season impacts the incidence and course 
of RA19–21, likely owing to circadian rhythms affecting pro-inflammatory cytokines22,23. This may be explained 
by effects of seasonal changes in vitamin D affecting the immune system24, perhaps through seasonal impact on 
relevant genes, independent of vitamin D metabolism25,26.
Our study design implies that one year remission is evaluated the same season as diagnosis was established, 
and the impact of season on disease activity at diagnosis will be mirrored in the remission-criteria applied one 
year after. Thus, the probability to observe one-year remission will be lower in patients diagnosed in winter. As 
Dtotal levels are lower in winter, we suggest this being a plausible explanation to our main finding: season is a 
strong confounder in the relationship between vitamin D and disease activity in RA. As season independently 
predicted one-year remission, we further suggest our results to be indicative of season of diagnosis being an 
important contextual factor in evaluation of RA disease-course. We advocate future research to take season into 
account when evaluating disease activity in early RA.
The primary outcome; remission, is evaluated as DAS28; a composite of subjective and objective 
disease-activity markers weighting pain and inflammation. Pain may persist in DAS28-remission27, whereas 
1,25(OH)2D supplementation is reported to significantly relieve pain in early RA28. As the CIMESTRA strategy 
included increased awareness of vitamin D intake, we assume that an eventual painful proximal myopathy owing 
to low vitamin D was improved during follow-up. In RA, 25OHD levels may be correlated to dietary intake29, 
while improvement of low serum vitamin D upon supplementation in RA is associated with improved treatment 
response30. Moreover, RA patients with low 25OHD and no vitamin D supplementation are less frequently in 
remission, compared to patients receiving relevant supplementation31. Likewise, abstaining from correction of 
low vitamin D levels is associated with increased recurrence-rates in some32, but not all studies33. However, the 
current study is not an interventional study investigating effects of vitamin D supplementation on remission. 
Patients were supplemented after individual physicians´ evaluation of vitamin D and calcium intake, with no 
knowledge of actual serum Dtotal level. Suggesting that sufficient vitamin D intake, concomitant to aggressive 
anti-inflammatory treatment, might partly explain the results, is only hypothesis-generating, despite plausible 
underlying biological associations supporting the hypotheses1. Though, data concerning which patients received 
supplementation is not available.
If a causal association between low vitamin D levels and high RA disease activity exists, it seems reasonable 
that patients with more active disease shows better treatment response upon the aggressive treatment-regimen 
and relevant vitamin D intake, thus explaining the higher remission-rate in the group with lower Dtotal. 
Furthermore, if a “low vitamin D RA subtype” exists, and low vitamin D levels are associated with higher disease 
activity and pain11, such patients may receive higher doses of anti-inflammatory medication, and be more likely 
to achieve remission, partly explaining the results.
Limitations of the current study include restrictions owing to the use of post-hoc analyses in a parental RCT, 
designed for other purposes: The study population is rather small, supported by several estimates having large 
95% CIs. However, to the best of knowledge, our study almost doubles observations upon which estimates can be 
made, compared to other studies evaluating vitamin D and remission in early RA14,15. The parental CIMESTRA 
Figure 1. Patient flow-diagram for year one in the original CIMESTRA study, according to Dtotal status at 
diagnosis - Abbreviations: Dtotal: the sum of 25OHD2 and 25OHD3.
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RCT investigated the additive effect of ciclosporine or placebo to an aggressive, treat-to-target strategy, and 50% 
received ciclosporine. Vitamin D metabolites evaluated in the current study were obtained prior to treatment, and 
were not affected by ciclosporine treatment. No adjustment for ciclosporine is done, as no significant association 
was found between ciclosporine and one year remission34.
Possible unmeasured residual-confounders must be considered: Relevant markers of calcium metabolism, 
such as calcium, phosphorous and parathyroid hormone are not evaluated. Neither, information concerning 
sun-exposure, the main-cause to cutaneous vitamin D production, is assessed. Besides, vitamin D levels have been 
reported to vary according to meat consumption35–37. However, we are unable to account for meat-consumption 
in the current study.
Another potential limitation is the dichotomization of Dtotal, applied in the current study: Cutpoint defining 
sufficient vitamin D levels varies greatly, depending on e.g. age, race, weight, sun-exposure and diet3. The interna-
tionally accepted cut-point defining low vitamin D is 50 nmol/l38. We acknowledge that dichotomization might 
lead to loss of more subtle details, and that it has been argued that higher levels of vitamin D might be necessary 
for better health outcomes39. However, we find that the use of a well-known cut-point, and the comparability to 
the few similar studies increase the external validity, interpretation and clinical use of our results.
To avoid overfitting our statistical models, we evaluated model fits by AIC and concluded that the fully 
adjusted model was the most realistic model. As different modelling scenarios resulted in inconsistency among 
results, we advocate for reproduction of our results before firm conclusions are made
We believe that our data can be applied to a Scandinavian population with newly diagnosed RA. Despite 
data collection at the millennium, the aggressive treat-to-target strategy is still the recommendations nowadays, 
increasing the external validity. Our results need to be reproduced, preferably in sufficiently powered studies with 
Low Dtotal (<50 nmol/L)
Normal Dtotal  
(≥50 nmol/L) Contrast between groups
Primary outcome: Remission. 
(%) N = 45 (71%) N = 51 (64%)
Crude analysisa:
OR 1.4, 95% CI (0.7; 2.7) p = 0.33
Logistic regressionb:
OR 1.4, 95% CI (0.7; 2.9) p = 0.34
Adjusted logistic regressionc:
OR 2.6, 95% CI (1.1; 5.9) p = 0.03
Best-case scenario assuming 
the 15 patients not evaluated 
for year on, all did achieved 
remission
N = 49 (73%) N = 62 (68%)
Crude analysisa:
OR 1.3, 95% CI (0.6; 2.6) p = 0.50
Logistic regressionb:
OR 1.3, 95% CI (0.6; 2.6) p = 0.51
Adjusted logistic regressionc:
OR 2.0 95% CI (0.9, 4.3) p = 0.09
Worst-case scenario assuming 
the 15 patients not evaluated 
for year one, all did not 
achieved remission
N = 45 (67%) N = 51 (56%)
Crude analysisa:
OR 1.6, 95% CI (0.8; 3.1) p = 0.16
Logistic regressionb:
OR 1.6, 95% CI (0.8; 3) p = 0.2
Adjusted logistic regressionc:
OR 2.9, 95% CI (1.3; 6.2) p = 0.01
Change in disease activity markers after 1 year according to Dtotal group at time of diagnosis
Change in HAQ Mean: −0.695% CI (−0.7; −0.5)
Mean: −0.6
95% CI (−0.7; −0.5)
Least Squares Mean Difference:
Crude analysis: −0.1, 95% CI (−0.2;0.1) p = 0.48
Change in NTJ Mean: −9.795%CI (−10.9; 8.8)
Mean: −8.6
95% CI (−9.5; 7.8)
Least Squares Mean Difference:
Crude analysis: 1.1, 95% CI (−0.2; 2.4) p = 0.09
Change in NSJ Mean: −8.895% CI (−9.3; −8.3)
Mean: −8.1
95% CI (−8.1; −7.7)
Least Squares Mean Difference:
Crude analysis: 0.7, 95% CI (0.0; 1.3) p = 0.04
Change in VASdoctor global
Mean: −47.7
95% CI (−51; −44.4)
Mean: −44.7
95% CI (−47.5; −41.8)
Least Squares Mean Difference:
Crude analysis: 3.2, 95% CI (−1.3; 7.5) p = 0.17
Change in VASpatient-pain
Mean: −29.7
95% CI (−34.9; −24.5)
Mean: −28.2
95% CI (−32.7; −23.6)
Least Squares Mean Difference:
Crude analysis: 1.6, 95% CI (−5.3; 8.5) p = 0.65
Change in VASpatient global
Mean: −31.6
95% CI (−37; −26.2)
Mean: −28.9
95% CI (−33.7; −24.1)
Least Squares Mean Difference:
Crude analysis: 2.7, 95% CI (−4.5; 10) p = 0.46
Change in ESR, mm/hour Mean: −12.895% CI (−16.3; −9.3)
Mean: −14.2
95% CI (−17.3; −11.1)
Least Squares Mean Difference:
Crude analysis: −1.4, 95% CI (−6.2; 3.3) p = 0.55
Change in CRP, mg/l Mean: −21.195% CI (−25.2; −16.9)
Mean: −20.4
95% CI (−24.1; −16.7)
Least Squares Mean Difference:
Crude analysis: 0.6, 95% CI (−4.9; 6.2) p = 0.82
Change in DAS28-CRP Mean: −395% CI (−3.3; −2.7)
Mean: −2.7
95% CI (−2.9; −2.4)
Least Squares Mean Difference:
Crude analysis:0.3, 95% CI (−0.1; 0.7) p = 0.08
Table 2. Achieving remission according to Dtotal at diagnosis. aCrude logistic regression; Dtotal group as 
independent variable, no other covariates. bSimple logistic regression, further containing age at diagnosis 
and sex. cMultiple logistic regression, further adjusted for symptom-duration prior to diagnosis, DAS28-
CRP at diagnosis and diagnosis established in winter (November to April). For all comparisons, the group 
having normal Dtotal (i.e defined as “not low”) is the reference. Abbreviations: Dtotal: The sum of 25OHD2 and 
25OHD3. BMI: Body Mass Index, ACPA: Anti Citrullinated Protein Antibodies, IgM-RF: Immunoglobulin M 
Rheumafactor, NTJ: Number of Tender Joints, NSJ: Number of Swollen Joints, VAS: Visual Analogue Score, 
HAQ: Health Assessment Questionnaire, CRP: C-reactive protein, DAS28-CRP Disease Activity Score, based 
on 28 joint count and CRP.
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vitamin D supplementation guided by serum vitamin D measurements, alongside to aggressive treatment and 
adjustment for season.
In conclusion, low vitamin Dtotal at time of diagnosis in early, treatment-naïve RA is associated with increased 
odds of achieving remission after one year, when adjusting for relevant confounding variables. Conceivably, this 
finding is mainly attributable to seasonal variation per se with low vitamin D levels as a potential amplifier. In 
order to elucidate the relationship between vitamin D status, disease activity and season of the year, follow-up 
visits at 6 months interval may be useful. In the meantime, clinicians and researchers should be aware of the 
potential impact by season on RA disease presentation.
Methods
patients and outcomes. One-hundred-and-sixty patients were recruited from five Danish University 
Clinics from October 1999 to October 2002 in the CIMESTRA-study. Eligibility criteria and treatment-strategy 
are described elsewhere34. One-hundred-and-fifty-eight patients had Dtotal (the sum of 25OHD2 and 25OHD3) 
and 1,25(OH)2D) measured prior to inclusion and treatment. One-Hundred-and-forty-three patients had 
DAS28-CRP calculated after one year, and were included in the current study. Patients were allocated to Dtotal 
group at time of diagnosis, dichotomized as low: Dtotal < 50 nmol/L or normal: Dtotal ≥ 50 nmol/L. Patients who 
reported insufficient vitamin D and calcium intake at time of diagnosis received daily oral supplements of vitamin 
D3 (800 IE/10 mcg) and calcium (1500 mg), according to national guidelines. Treating physician decided eventual 
need for supplementation unaware of actual serum vitamin D levels, as serum levels were evaluated from biobank 
for this current study. NTJ, Number of Swollen Joints – 28 joint count (NSJ), Visual Analogue Scores (VAS): 
VASglobal-doctor, VASglobal-patient, VASpain-patient, CRP, DAS28-CRP, Health Assessment Questionnaire (HAQ), Anti 
Citrullinated Protein Antibodies (ACPA), Immunoglobulin M-Rheuma Factor (IgM-RF) and season of diagno-
sis (Winter defined as diagnosis established between November and April) were evaluated at time of diagnosis. 
DAS28-CRP ≤ 2.6 at one year was defined as remission. (See Fig. 1).
Measurement of the vitamin D metabolites. 25OHD2 and 25OHD3 in serum were analyzed with iso-
tope dilution liquid chromatography-mass spectrometry (LC-MS/MS) using calibrators traceable to international 
standard reference material NIST SRM 97240. Mean coefficients of variation (CVs) of 25OHD3 were 9.6% and 
8.1% at 25 nmol/L and 48 nmol/L, respectively, and for 25OHD2, 8.5% and 8.0% at levels of 23 and 64 nmol/L, 
respectively41.
1,25(OH)2D was analyzed by radio Immuno Assays (RIA)42 after immune-extraction of the samples. 
(1,25-dihydroxy vitamin D RIA, IDS, Boldon, UK) Mean intra-assay (well-to-well) CV were 6.8% and 9.0% at 
levels of 90 and 220 pmol/L, respectively.
Routine laboratory assessments. IgM-RF was detected by enzyme-linked immunosorbent assay 
(ELISA). ACPA-IgG antibodies were determined by a second-generation ELISA (Immunoscan RA kit, 
Euro-diagnostica AB, Malmo, Sweden) Serum CRP was measured using standard laboratory measures.
Statistical methods. Differences between Dtotal groups for dichotomous variables at time of diagnosis were 
evaluated by Chi2 test. Wilcoxon-Rank-Sum test evaluated differences in continuously variables. Underlying 
assumptions were evaluated through study-design.
Univariate, logistic regression was performed for Dtotal, comparing levels <50 nmol/L to levels ≥50 nmol/L, 
in predicting DAS28-CRP ≤ 2.6 after one year. This is defined as the “crude model”. In the model defined as the 
“partially adjusted model”, sex and age at diagnosis were included, whereas symptom-duration prior to diagno-
sis, DAS28-CRP and diagnosis established at winter were further included in the fully adjusted model. These 
variables were chosen prior to analysis because of their previously reported ability to predict clinical remission43. 
or close physiological relation to vitamin D4. Despite patients originally randomized 1:1 to ciclosporine, it was 
decided not to adjust for ciclosporine, as no association with one-year remission was found for ciclosporine in the 
original CIMESTRA study34.
Further aiming at evaluating the delicate interplay between variables included in the model, a step-by-step 
approach was used, including sex, age, symptom duration, DAS28-CRP at diagnosis and season of diagnosis in a 
logistic regression one by one.
OR for remission with inclusion of the 
mentioned variables
Crude analysis (Dtotal and remission) OR 1.4, 95% CI (0.7;2.9) p = 0.33
Adjusted for sex OR 1.4, 95% CI (0.7;2.9) p = 0.33
Adjusted for sex and age OR 1.4, 95% CI (0.7; 2.9) p = 0.33
Adjusted for sex, age and disease-duration OR 1.4, 95% CI (0.7;3.01) p = 0.30
Adjusted for sex, age, disease-duration and DAS28 OR 1.8, 95% CI (0.8;2.9) p = 0.13
Adjusted for sex, age, disease-duration, DAS28 and 
diagnosis established at winter. OR 2.6, 95% CI (1.1; 5.9) p = 0.03
Table 3. Stepwise regression, including a priori chosen variables one by one. Abbreviations: Dtotal: The sum of 
25OHD2 and 25OHD3. DAS28-CRP Disease Activity Score, based on 28 joint count and CRP.
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The model was subsequently evaluated for interaction between vitamin D and season of diagnosis, as a close 
relationship exists between season and circulating Dtotal. Likelihood ratios tests were used to evaluate model fit. 
AIC and BIC assesses the model fit when taking number of co-variates included into account, and thus estimates 
the risk of over-fitting. Emphasis is put on AIC, while BIC is also presented.
To test the robustness of the model, propensity score analysis was applied to evaluate the potential biasing 
impact of other variables on the outcome. The propensity score analysis included BMI, ACPA, IgM-RF, NSJ, NTJ, 
VASglobal-patient, HAQ and CRP at time of diagnosis to determine, if confounding by any of these factors was biasing 
the results.
The potential impact of the missing remission-data of the 15 patients not included in year one was evaluated 
using best- and worst case scenarios, coding all missing patients as being either in remission (“Best case”) or not 
in remission (“Worst case”).
Concerning 1,25(OH)2D, similar analyses were performed as for Dtotal, comparing lowest and middle tertile 
to highest tertile.
Significance is defined as the 5% level. Stata IC 1544 is used for statistical analyses.
ethics and consent
The study complies with the Oviedo and Helsinki declarations. The protocol was approved by Ethics Committee 
Region Midt (M-1959–98) and registered at www.clinicaltrials.gov (NCT00209859). All patients received verbal 
and written information prior to enrolment, and gave written consent at baseline.
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